+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Next-Generation Sequencing on Drug Development Market

  • PDF Icon

    Report

  • 177 Pages
  • August 2023
  • Region: Global
  • BCC Research
  • ID: 5869917
Description Jump to:

The scope of this report includes NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS in drug development are given for 2020, 2021, 2022, 2023 and 2028.

This report reviews the NGS technologies and explains why NGS is important in drug development. It then discusses some of the significant research initiatives that impact NGS. The main market-driving forces are also discussed.

This report examines the markets by product type, end user and region. This report provides market data and forecasts for NGS by product type, including instruments, consumables and services for drug development.

Specific geographic markets are discussed, including North America, Europe, Asia-Pacific and the Rest of the World.

The report summarizes the main industry acquisitions and strategic alliances from Jan. 2020, through Dec. 2022, including key alliance trends.

Report Includes

  • 52 data tables and 39 additional tables
  • An overview of the global markets for next-generation sequencing on drug development
  • Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Highlights of the market potential and characterization of next-generation sequencing on drug development market by product, service, end-user type, and region
  • Examination of the key drivers and constraints that will shape the market for next-generation sequencing on drug development and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and subsegments
  • Coverage of recent advances, emerging technologies, and developments of the industry
  • Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
  • Profiles of the key companies of the industry, including 10x Genomics, Bio-Rad Laboratories Inc., Oxford Nanopore Technologies, Qiagen and Takara Bio Inc.

Table of Contents

Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • Research Methodology
  • Information Sources
  • Geographic Breakdown
Chapter 2 Summary and Highlights
  • Market Outlook
  • Market Summary
Chapter 3 Market Overview
  • Introduction
  • Technology Background
  • Structure and Importance of Dna
  • Dna Sequencing Technologies
  • Whole Genome Sequencing
  • Targeted Resequencing
  • Chip Sequencing
  • Rna Sequencing
  • Methylation Sequencing
  • History of Dna Sequencing
  • Sanger Sequencing
  • Introduction to Next Generation Sequencing (Ngs)
  • Advantages of Ngs
  • Roche 454 Pyrosequencing
  • Illumina Ngs
  • Thermo Fisher Scientific (Life Technologies) Ngs
  • Sequencing Instruments
  • Benchtop Sequencers
  • Informatics Technologies
  • Ngs in Drug Development
  • Ngs Service Providers
Chapter 4 Market Dynamics
  • Market Drivers
  • Increasing R&D Activities Using Ngs Technologies
  • Increase in Healthcare Expenditure
  • Technological Advancements in Sequencing Platforms
  • Shift Towards Precision Medicine
  • Growing Demand of Ngs for Designing Individualized Medicine to Cancer Patients
  • High Accuracy and Low Cost
  • Market Restraints
  • Limitations Associated With Ngs Technology
  • Other Clinical Sequencing Technology Challenges
  • Market Opportunities
  • Rising R&D in Ngs Creates Lucrative Opportunities for Manufacturers
Chapter 5 Ngs in Drug Development by Product Type
  • Introduction
  • Instruments
  • Consumables
  • Services
  • Chapter 6 Ngs Market in Drug Development by End-user
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Centers
  • Other End-users
Chapter 7 Ngs Market in Drug Development by Region
  • Market Overview and Discussion
  • North America
  • Asia-Pacific
  • Europe
  • Rest of the World
Chapter 8 Sustainability of Ngs in Drug Development: An Esg Perspective
  • Introduction to Esg
  • Sustainability of Ngs in Drug Development: An Esg Perspective
  • Key Esg Issues
  • Consumer Attitudes Towards Esg
  • Industry Esg Performance Analysis
  • Case Study
  • Environment
  • Social
  • Governance
  • Concluding Remarks
Chapter 9 Emerging Technologies and Developments
  • Overview
  • Emerging Technologies in the Market
  • Application of Artificial Intelligence (Ai) in Ngs
  • Single-Molecule Real-Time Sequencing
  • Nanopore Technology
  • Microscopy-Based Sequencing
Chapter 10 Patent Analysis
  • Introduction
  • Patents on Ngs by Region
Chapter 11 M&A and Funding Outlook
  • M&A Analysis
Chapter 12 Competitive Landscape
  • Global Company Ranking
  • Global Company Ranking for Ngs Instruments in Drug Development
  • Global Company Ranking for Ngs Consumables in Drug Development
  • Global Company Ranking for Ngs Services in Drug Development
Chapter 13 Company Profiles
  • 10X Genomics
  • Agilent Technologies Inc.
  • Bgi (Beijing Genomics Institute)
  • Bio-Rad Laboratories Inc.
  • Cd Genomics
  • Illumina Inc.
  • Integrated Dna Technologies Inc.
  • Micronoma
  • New England Biolabs
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California Inc.
  • Perkinelmer Inc.
  • Promega Corp.
  • Psomagen Inc.
  • Precision for Medicine, Formerly Apocell
  • Qiagen
  • Roche Holding AG
  • Thermo Fisher Scientific Inc.
  • Takara Bio Inc.
  • Tecan Group Ltd.
Chapter 14 Appendix: Acronyms
List of Tables
Summary Table: Global Market for NGS in Drug Development, by Region, Through 2028
Table 1: DNA Translation and Transcription
Table 2: Long-range DNA Structure
Table 3: DNA Sequencing Workflow
Table 4: DNA Sequencing Historical Timeline, 1955-2017
Table 5: Sequencing Technology Development, 1990-2020+
Table 6: Cost to Sequence a Single Human Genome, 2001-2018
Table 7: Sanger Sequencing Summary
Table 8: Sanger Sequencing Improvements
Table 9: NGS Technologies
Table 10: Roche NGS Workflow
Table 11: Illumina NGS Workflow
Table 12: Thermo Fisher NGS Workflow
Table 13: NGS Instruments
Table 14: Benchtop and Handheld Sequencer Platforms
Table 15: Characteristics of NGS Platforms
Table 16: NGS Bioinformatics Workflow
Table 17: Sequence Annotation Steps
Table 18: NGS Service Providers
Table 19: NGS Cost per Sample
Table 20: Future Challenges for Implementing NGS
Table 21: Global Market for NGS in Drug Development, by Product Type, Through 2028
Table 22: Global Market for NGS Instruments in Drug Development, by Region, Through 2028
Table 23: Global Market for NGS Consumables in Drug Development, by Region, Through 2028
Table 24: Global Market for NGS Services in Drug Development, by Region, Through 2028
Table 25: Global Market for NGS in Drug Development, by End User, Through 2028
Table 26: Global Market for NGS in Drug Development, by Region, Through 2028
Table 27: North American Market for NGS in Drug Development, by Country, Through 2028
Table 28: Asia-Pacific Market for NGS in Drug Development, by Country, Through 2028
Table 29: European Market for NGS in Drug Development, by Country, Through 2028
Table 30: RoW Market for NGS in Drug Development, Through 2028
Table 31: Key Focus Areas in ESG Metrics
Table 32: Net-Zero GHG Commitments, Major NGS Companies
Table 33: ESG Rankings for Major NGS Companies, 2023*
Table 34: CDP Scope Card for Major NGS Companies, 2022
Table 35: U.S. Patent Related to NGS
Table 36: Worldwide Patent Related to NGS
Table 37: European Patents Related to NGS
Table 38: Chinese Patents Related to NGS
Table 39: Japanese Patents Related to NGS
Table 40: Global Market Rankings, NGS in Drug Development, by Manufacturer, 2022
Table 41: Global Market Rankings for NGS Instruments in Drug Development, by Manufacturer, 2022
Table 42: Global Market Rankings for NGS Instruments in Drug Development, by Manufacturer, 2022
Table 43: Global Market Rankings for NGS Services in Drug Development, by Manufacturer, 2022
Table 44: 10x Genomics: Net Annual Revenue, by Segment, 2020-2022
Table 45: 10x Genomics: Net Annual Revenue, by Region/Country, 2020-2022
Table 46: 10x Genomics: Products and Services
Table 47: Agilent Technologies Inc.: Net Revenue, by Segment, 2020-2022
Table 48: Agilent Technologies Inc.: Net Revenue, by Business Segment, 2020-2022
Table 49: Agilent Technologies Inc.: Net Revenue, by End Market, 2020-2022
Table 50: Agilent Technologies Inc.: Revenue, by Type, 2020-2022
Table 51: Agilent Technologies Inc.: Net Revenue, by Region, 2020-2022
Table 52: Agilent Technologies Inc.: NGS Products
Table 53: BGI: Products and Services
Table 54: Bio-Rad Laboratories Inc.: Product Portfolio
Table 55: Bio-Rad Laboratories Inc.: Company Financials, 2020-2022
Table 56: Bio-Rad Laboratories Inc.: Net Revenue, by Business Segment, 2020-2022
Table 57: Bio-Rad Laboratories Inc.: Net Revenue, by Region/Country, 2020-2022
Table 58: Illumina Inc.: Net Revenue, 2020-2022
Table 59: Illumina Inc.: Revenue, by Source, 2021 and 2022
Table 60: Illumina Inc.: Net Revenue, by Region, 2020-2022
Table 61: Illumina Inc.: Drug Discovery and Development Products
Table 62: Oxford Nanopore Technologies: Products and Services
Table 63: Oxford Nanopore Technologies: Net Revenue, by Segment, 2020-2022
Table 64: Oxford Nanopore Technologies: LSRT Revenue, by Region/Country, 2020-2022
Table 65: Pacific Biosciences of California Inc.: Net Revenue, by Segment, 2020-2022
Table 66: Pacific Biosciences of California Inc.: Net Revenue, by Region, 2020-2022
Table 67: PacBio: Products and Services
Table 68: PerkinElmer Inc.: Net Revenue, by Operating Segment, 2020-2022
Table 69: PerkinElmer Inc.: Net Revenue, by Business Segment, 2020-2022
Table 70: PerkinElmer Inc.: Net Revenue, by Region/Country, 2020-2022
Table 71: Qiagen: Financial Revenue, 2020-2022
Table 72: Qiagen: Net Revenue, by Customer Class, 2020-2022
Table 73: Qiagen: Net Revenue, by Product Group, 2020-2022
Table 74: Qiagen: Net Revenue, by Region/Country, 2020-2022
Table 75: Qiagen: NGS Products and Services
Table 76: Roche Holding AG: Net Revenue, by Business Segment, 2020-2022
Table 77: Roche Holding AG: Diagnostics Revenue, by Segment, 2020-2022
Table 78: Roche Holding AG: Pharmaceuticals Revenue, by Segment, 2021 and 2022
Table 79: Roche Holding AG: Net Revenue, by Region/Country, 2021 and 2022
Table 80: Roche Holding AG: NGS Products and Services
Table 81: Thermo Fisher Scientific Inc.: Net Revenue, by Segment, 2020-2022
Table 82: Thermo Fisher Scientific Inc.: Net Revenue, by Segment, 2020-2022
Table 83: Thermo Fisher Scientific Inc.: Net Revenue, by Region, 2020-2022
Table 84: Thermo Fisher Scientific Inc.: Products and Services
Table 85: Takara Bio Inc.: Net Revenue, by Segment, 2021 and 2022
Table 86: Takara Bio Inc.: Net Revenue, by Region/Country, 2020-2022
Table 87: Tecan Group Ltd.: Company Financials, 2020 and 2022
Table 88: Tecan Group Ltd.: Net Revenue, by Business Segment, 2020-2022
Table 89: Tecan Group Ltd.: Net Revenue, by Region, 2022
Table 90: Acronyms Used in This Report

List of Figures
Summary Figure A: Global Market for NGS in Drug Development, by Region, 2020-2028
Summary Figure B: Global Market Shares of NGS in Drug Development, by Region, 2022
Figure 1: Whole Genome Sequencing
Figure 2: Number of NGS Tests, Research Activities, Different Global Centers, 2023
Figure 3: The Road from NGS to Personalized Medicine
Figure 4: Global Market for NGS in Drug Development, by Product Type, 2020-2028
Figure 5: Global Market Shares of NGS in Drug Development, by Product Type, 2022
Figure 6: Global Market for NGS Instruments in Drug Development, by Region, 2020-2028
Figure 7: Global Market Shares of NGS Instruments in Drug Development, by Region, 2022
Figure 8: Global Market for NGS Consumables in Drug Development, by Region, 2020-2028
Figure 9: Global Market Shares of NGS Consumables in Drug Development, by Region, 2022
Figure 10: Global Market for NGS Services in Drug Development, by Region, 2020-2028
Figure 11: Global Market Shares of NGS Services in Drug Development, by Region, 2022
Figure 12: Global Market for NGS in Drug Development, by End User, 2020-2028
Figure 13: Global Market Shares of NGS in Drug Development, by End User, 2022
Figure 14: Global Market for NGS in Drug Development, by Region, 2020-2028
Figure 15: Global Market Shares of NGS in Drug Development, by Region, 2022
Figure 16: North American Market for NGS in Drug Development, by Country, 2020-2028
Figure 17: North American Market Shares of NGS in Drug Development, by Country, 2022
Figure 18: Asia-Pacific Market for NGS in Drug Development, by Country, 2020-2028
Figure 19: Asia-Pacific Market Shares of NGS in Drug Development, by Country, 2022
Figure 20: European Market for NGS in Drug Development, by Country, 2020-2028
Figure 21: European Market Shares of NGS in Drug Development, by Country, 2022
Figure 22: How a Strong ESG Proposition Benefits Businesses
Figure 23: Research Communities, Key Sustainable Practices, Research Laboratories
Figure 24: Illumina Inc.’s Most Material ESG Issues
Figure 25: Emerging Technologies in the NGS Market in Drug Development
Figure 26: 10x Genomics: Net Revenue, 2020-2022
Figure 27: 10x Genomics: Revenue Share, by Segment, 2022
Figure 28: 10x Genomics: Revenue Share, by Region/Country, 2022
Figure 29: Agilent Technologies Inc.: Revenue Share, by Segment, 2022
Figure 30: Agilent Technologies Inc.: Revenue Share, by Business Segment, 2022
Figure 31: Agilent Technologies Inc.: Revenue Share, by End Market, 2022
Figure 32: Agilent Technologies Inc.: Revenue Share, by Type, 2022
Figure 33: Agilent Technologies Inc.: Revenue Share, by Region, 2022
Figure 34: Bio-Rad Laboratories Inc.: Revenue Share, by Business Segment, 2022
Figure 35: Bio-Rad Laboratories Inc.: Revenue Share, by Region/Country, 2022
Figure 36: Illumina Inc.: Revenue Share, by Segment, 2022
Figure 37: Illumina Inc.: Revenue Share, by Segment, 2022
Figure 38: Oxford Nanopore Technologies: Net Revenue, 2020-2022
Figure 39: Oxford Nanopore Technologies: Revenue Share, by Region/Country, 2022
Figure 40: Pacific Biosciences of California Inc.: Revenue Share, by Segment, 2022
Figure 41: Pacific Biosciences of California Inc.: Revenue Share, by Region, 2022
Figure 42: PerkinElmer Inc.: Revenue Share, by Operating Segment, 2022
Figure 43: PerkinElmer Inc.: Revenue Share, by Business Segment, 2022
Figure 44: PerkinElmer Inc.: Revenue Share, by Region/Country, 2022
Figure 45: Qiagen: Revenue Share, by Segment, 2022
Figure 46: Qiagen: Revenue Share, by Customer Class, 2022
Figure 47: Qiagen: Revenue Share, by Product Group, 2022
Figure 48: Qiagen: Revenue Share, by Region/Country, 2022
Figure 49: Roche Holding AG: Revenue Share, by Business Segment, 2022
Figure 50: Roche Holding AG: Diagnostics Revenue Share, by Segment, 2022
Figure 51: Roche Holding AG: Pharmaceuticals Revenue Share, by Segment, 2022
Figure 52: Roche Holding AG: Revenue Share, by Region/Country, 2022
Figure 53: Thermo Fisher Scientific Inc.: Net Revenue, 2020-2022
Figure 54: Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2022
Figure 55: Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2022
Figure 56: Thermo Fisher Scientific Inc.: Revenue Share, by Region, 2022
Figure 57: Takara Bio Inc.: Net Revenue, 2020-2022
Figure 58: Takara Bio Inc.: Revenue Share, by Segment, 2022
Figure 59: Takara Bio Inc.: Revenue Share, by Region/Country, 2022
Figure 60: Tecan Group Ltd.: Revenue Share, by Business Segment, 2022
Figure 61: Tecan Group Ltd.: Revenue Share, by Region, 2022

Executive Summary

Next-generation sequencing (NGS) is based on the concept of massive parallel sequencing that produces very large numbers of relatively small reads. NGS techniques revolutionized genetic research and filled a gap in everyday research tools to address complex genomic research questions. This essential tool in many research fields (de-novo genome sequencing, comparative genomics or gene expression and gene regulation studies) is driving discovery and enabling the future of personalized medicine.

NGS in drug discovery and development is focused on target identification and genetically stratified clinical trials. The wealth of human genetic information can be leveraged to identify drug targets, validate therapeutic hypotheses and predict the potential safety of inhibitory compounds aimed at molecular targets. NGS has the potential to uncover many mutations associated with genetic diseases and to identify target genes for future drug development endeavors.

Adoption of technologies will expand understanding of the genetic basis of human disease, help identify novel compounds or reuse existing compounds, increase drug efficacy, reduce adverse reactions and ultimately facilitate personalized therapies. Currently, the pharmaceutical industry is performing population scale NGS analysis to discover new knowledge about human diseases, with focused NGS analysis on clinical trials to identify biomarkers for drug efficacy or safety. In the near future, NGS may bring new marketed compounds. More genetically stratified clinical trials could be conducted to recruit specific subsets of participants based on genetic profiles and other clinical biomarkers.

The global NGS market in drug development was valued at nearly $1.1 billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of 17.7% to reach $2.9 billion by 2028. Growth in this market comes from increasing R&D activities using NGS technologies, the rise in technological advancements (especially nanopore sequencing in NGS and discovery applications that require NGS technology) is boosting the growth NGS in the drug development market.

For the purposes of this report, the global market for NGS in drug development is segmented into product type, end user and geography. The NGS market in drug development product types include instruments, consumables and services. Pharmaceutical and biotechnology companies are concentrating on launching novel NGS instruments that are used for drug development. In Oct. 2022, Illumina Inc. launched a strategic research collaboration with AstraZeneca, a global, science-led biopharmaceutical company, to accelerate drug target discovery by connecting strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will consider whether an integrated framework of these technologies can increase the work and confidence of target discovery to see promising drugs based on human omics insights. Therefore, such innovations and technologically advanced product launches in the NGS market in drug development will likely drive segment growth over the forecast period.

Companies Mentioned

  • 10X Genomics
  • Agilent Technologies Inc.
  • Bgi (Beijing Genomics Institute)
  • Bio-Rad Laboratories Inc.
  • Cd Genomics
  • Illumina Inc.
  • Integrated Dna Technologies Inc.
  • Micronoma
  • New England Biolabs
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California Inc.
  • Perkinelmer Inc.
  • Promega Corp.
  • Psomagen Inc.
  • Precision for Medicine, Formerly Apocell
  • Qiagen
  • Roche Holding AG
  • Thermo Fisher Scientific Inc.
  • Takara Bio Inc.
  • Tecan Group Ltd.

Table Information

Report AttributeDetails
No. of Pages177
PublishedAugust 2023
Forecast Period2023 - 2028
Estimated Market Value ( USD ) in 2023 $ 1.3 Billion
Forecasted Market Value ( USD ) by 2028 $ 2.9 Billion
Compound Annual Growth Rate17.7%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Next-Generation Sequencing: Emerging Clinical Applications and Global Markets - Product Image

Next-Generation Sequencing: Emerging Clinical Applications and Global Markets

  • Report
  • 492 Pages
  • Global
From
Clinical Next-Generation Sequencing (NGS) Data Analysis Global Market Report 2024 - Product Image

Clinical Next-Generation Sequencing (NGS) Data Analysis Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Next Generation Sequencing - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Next Generation Sequencing - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Next-Generation Sequencing Market Size and Forecasts 2020-2030: Global and Regional Share, Trends, and Growth Opportunity Analysis by Technology; Application; and End-User - Product Image

Next-Generation Sequencing Market Size and Forecasts 2020-2030: Global and Regional Share, Trends, and Growth Opportunity Analysis by Technology; Application; and End-User

  • Report
  • 116 Pages
  • Global
From
Next Generation Sequencing Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Opportunity Company Analysis - Product Image

Next Generation Sequencing Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Opportunity Company Analysis

  • Report
  • 235 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.